Taysha Gene Therapies Inc (TSHA)
2.37
-0.11
(-4.44%)
USD |
NASDAQ |
May 08, 16:00
2.36
-0.01
(-0.42%)
After-Hours: 20:00
Taysha Gene Therapies Free Cash Flow (Quarterly): -16.13M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -16.13M |
| September 30, 2023 | -21.45M |
| June 30, 2023 | -18.72M |
| March 31, 2023 | -24.08M |
| December 31, 2022 | 12.40M |
| September 30, 2022 | -31.83M |
| June 30, 2022 | -41.47M |
| March 31, 2022 | -52.37M |
| Date | Value |
|---|---|
| December 31, 2021 | -48.78M |
| September 30, 2021 | -35.94M |
| June 30, 2021 | -31.31M |
| March 31, 2021 | -22.57M |
| December 31, 2020 | -25.90M |
| September 30, 2020 | -6.747M |
| June 30, 2020 | -5.466M |
| March 31, 2020 | -1.699M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-52.37M
Minimum
Mar 2022
12.40M
Maximum
Dec 2022
-23.25M
Average
-23.33M
Median
Free Cash Flow (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | -4.958M |
| Lifecore Biomedical Inc | -- |
| Relmada Therapeutics Inc | -10.25M |
| ACADIA Pharmaceuticals Inc | 85.39M |
| Cyclacel Pharmaceuticals Inc | -3.91M |